The DOI matches its Crossref record; 110 of the 110 references it cites were found in a registry or an index.
Fibroblast growth factor 21: a regulator of metabolic disease and health span
Open accessAbstract
Fibroblast growth factor 21 (FGF21) is a potent endocrine regulator with physiological effects on glucose and lipid metabolism and thus garners much attention for its translational potential for the management of obesity and related metabolic syndromes. FGF21 is mainly expressed in several metabolically active tissue organs, such as the liver, adipose tissue, skeletal muscle, and pancreas, with profound effects and therapeutic relevance. Emerging experimental and clinical data point to the demonstrated metabolic benefits of FGF21, which include, but are not limited to, weight loss, glucose and lipid metabolism, and insulin sensitivity. In addition, FGF21 also acts directly through its coreceptor β-klotho in the brain to alter light-dark cycle activity. In this review, we critically appraise current advances in understanding the physiological actions of FGF21 and its role as a biomarker of various metabolic diseases, especially type 2 diabetes mellitus. We also discuss the potentially exciting role of FGF21 in improving our health and prolonging our life span. This information will provide a fuller understanding for further research into FGF21, as well as providing a scientific basis for potentially establishing health care guidelines for this promising molecule.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Several findings demonstrate that the overexpression of FGF21 improves healthspan”
From Human Aging and Longevity Are Characterized by High Levels of Mitokines (2019) · cites this paper as [17]
Citations
Cites
Stevens, P. E., Levin, A., & for the Kidney Disease: Improving Global Outcomes Chronic Kidney Disease Guideline Development Work Group Members* (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-158-11-201306040-00007 · Cited by 3,607
Kenyon, C. J. (2010) · Nature · doi:10.1038/nature08980 · Cited by 2,739
FGF-21 as a novel metabolic regulator
Kharitonenkov, A., Shiyanova, T. L., Koester, A., Ford, A. M., Micanovic, R., Galbreath, E. J., Sandusky, G. E., Hammond, L. J., Moyers, J. S., Owens, R. A., et al. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23606 · Cited by 2,125
Roles of PPARs in health and disease
Kersten, S., Desvergne, B., & Wahli, W. (2000) · Nature · doi:10.1038/35013000 · Cited by 1,956
Frederich, R. C., Hamann, A., Anderson, S., Löllmann, B., Lowell, B. B., & Flier, J. S. (1995) · Nature Medicine · doi:10.1038/nm1295-1311 · Cited by 1,660
Inagaki, T., Dutchak, P., Zhao, G., Ding, X., Gautron, L., Parameswara, V., Li, Y., Goetz, R., Mohammadi, M., Esser, V., et al. (2007) · Cell Metabolism · doi:10.1016/j.cmet.2007.05.003 · Cited by 1,504
Badman, M. K., Pissios, P., Kennedy, A. R., Koukos, G., Flier, J. S., & Maratos-Flier, E. (2007) · Cell Metabolism · doi:10.1016/j.cmet.2007.05.002 · Cited by 1,495
FGF21 regulates PGC-1α and browning of white adipose tissues in adaptive thermogenesis
Fisher, F. M., Kleiner, S., Douris, N., Fox, E. C., Mepani, R. J., Verdeguer, F., Wu, J., Kharitonenkov, A., Flier, J. S., Maratos-Flier, E., et al. (2012) · Genes & Development · doi:10.1101/gad.177857.111 · Cited by 1,478
The Endocrine Regulation of Aging by Insulin-like Signals
Tatar, M., Bartke, A., & Antebi, A. (2003) · Science · doi:10.1126/science.1081447 · Cited by 1,327
Xu, J., Lloyd, D. J., Hale, C., Stanislaus, S., Chen, M., Sivits, G., Vonderfecht, S., Hecht, R., Li, Y.-S., Lindberg, R. A., et al. (2009) · Diabetes · doi:10.2337/db08-0392 · Cited by 1,151
Research works printed but not linked: 3
- 10.1210/mend.16.6.0845 · DOI · Paper page
- Kharitonenkov A, 2009, Curr Opin Investig Drugs, 10, 359
- Zhang Q, 2015, Am J Cancer Res, 5, 1762
Cited by
Sorted by citations
The Klotho proteins in health and disease
Kuro-o, M. (2019) · Nature Reviews Nephrology · doi:10.1038/s41581-018-0078-3 · Cited by 707
Human Aging and Longevity Are Characterized by High Levels of Mitokines
Conte, M., Ostan, R., Fabbri, C., Santoro, A., Guidarelli, G., Vitale, G., Mari, D., Sevini, F., Capri, M., Sandri, M., et al. (2019) · The Journals of Gerontology: Series A · doi:10.1093/gerona/gly153 · Cited by 219
“Higher levels of circulating FGF21 attenuate acute metabolic disorders and collaborate to extend life span (16,17).”
BackgroundSandireddy, R., Sakthivel, S., Gupta, P., Behari, J., Tripathi, M., & Singh, B. K. (2024) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2024.1433857 · Cited by 235
The road ahead for health and lifespan interventions
Gonzalez-Freire, M., Diaz-Ruiz, A., Hauser, D., Martinez-Romero, J., Ferrucci, L., Bernier, M., & de Cabo, R. (2020) · Ageing Research Reviews · doi:10.1016/j.arr.2020.101037 · Cited by 118
Inflammaging, hormesis and the rationale for anti-aging strategies
Santoro, A., Martucci, M., Conte, M., Capri, M., Franceschi, C., & Salvioli, S. (2020) · Ageing Research Reviews · doi:10.1016/j.arr.2020.101142 · Cited by 121
Metadata
- Authors
- Xie, T., & Leung, P. S.
- Affiliations
- Chinese University of Hong Kong (HK)
- Corresponding author
- Leung, Po Sing
- Venue
- American Journal of Physiology-Endocrinology and Metabolism
- Publisher
- American Physiological Society
- Published
- 2017-09-01
- Volume
- 313
- Issue
- 3
- Pages
- E292-E302
- ISSN
- 0193-1849 (ISSN-L)
- 1522-1555
- PMC
- PMC5625087
- OpenAlex
- W2620038295
- Cited by
- 121
- References
- 110
- Citations by year
- 2026: 15 · 2025: 13 · 2024: 13 · 2023: 12 · 2022: 13 · 2021: 17 · 2020: 14 · 2019: 13 · 2018: 11
- FWCI
- 0.97
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- American Journal of Physiology-Endocrinology and Metabolism (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Research Grants Council of Hong Kong (14107415)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fibroblast Growth Factor Research
- Health Sciences › Medicine › Nephrology › Parathyroid Disorders and Treatments
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › GDF15 and Related Biomarkers
- Keywords
- FGF21, metabolic disorders, healthspan, obesity, type 2 diabetes, glucose metabolism, lipid metabolism, insulin sensitivity, β-Klotho, circadian rhythm, biomarkers, weight loss, adipose tissue, liver
- MeSH terms
- Klotho Proteins, Adipose Tissue, Circadian Rhythm, Diabetes Mellitus, Type 2, Fibroblast Growth Factors, Humans, Insulin Resistance, Liver, Longevity, Membrane Proteins, Obesity, Pancreas, Biomarkers, Muscle, Skeletal
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
